
Scientists at UW Medicine and the NIH have created an experimental flu vaccine that spurs broad immunity in animal trials
Researchers have developed experimental flu shots that protect animals from a wide variety of seasonal and pandemic influenza strains. The vaccine product is currently being advanced toward clinical testing. If proven safe and effective, these next-generation influenza vaccines may replace current seasonal options by providing protection against many more strains that current vaccines do not adequately cover.
A study detailing how the new flu vaccines were designed and how they protect mice, ferrets, and nonhuman primates appears in the March 24 edition of the journal Nature. This work was led by researchers at the University of Washington School of Medicine and the Vaccine Research Center part of the National Institute of Allergy and Infectious Diseases at the National Institutes of Health.

Influenza virus causes an estimated 290,000–650,000 deaths per year. Available flu vaccines, which need to be taken seasonally, often fail to protect against many circulating flu strains that cause illness, and the threat of another influenza pandemic looms.
“Most flu shots available today are quadrivalent, meaning they are made from four different flu strains. Each year, the World Health Organization makes a bet on which four strains will be most prevalent, but those predictions can be more or less accurate. This is why we often end up with ‘mismatched’ flu shots that are still helpful but only partially effective,” said lead author Daniel Ellis, a research scientist in the laboratory of Neil King. King is an assistant professor of biochemistry at the UW School of Medicine and a researcher at the Institute for Protein Design at UW Medicine.
To create improved influenza vaccines, the team attached hemagglutinin proteins from four different influenza viruses to custom-made protein nanoparticles. This approach enabled an unprecedented level of control over the molecular configuration of the resulting vaccine and yielded an improved immune response compared to conventional flu shots. The new nanoparticle vaccines, which contain the same four hemagglutinin proteins of commercially available quadrivalent influenza vaccines, elicited neutralizing antibody responses to vaccine-matched strains that were equivalent or superior to the commercial vaccines in mice, ferrets, and nonhuman primates. The nanoparticle vaccines—but not the commercial vaccines —also induced protective antibody responses to viruses not contained in the vaccine formulation. These include avian influenza viruses H5N1 and H7N9, which are considered pandemic threats.
The responses that our vaccine gives against strain-matched viruses are really strong, and the additional coverage we saw against mismatched strains could lower the risk of a bad flu season,” said Ellis.
Original Article: Nanoparticle flu shot blocks seasonal and pandemic strains
More from: University of Washington School of Medicine | National Institutes of Health
The Latest Updates from Bing News & Google News
Go deeper with Bing News on:
Experimental flu vaccine
- I need a flu shot and a COVID booster. Can I get them at the same time?
Cases of the flu and COVID are set to rise over winter, with many people looking to get vaccinated against both viruses.
- Could this be the beginning of the end for fall flu shots?
Specifically, the flu vaccine. The National Institutes of Health announced last week that it is enrolling volunteers for a clinical trial of an experimental flu vaccine that would cover many ...
- Could this be the beginning of the end for fall flu shots?
Researchers are tapping the same mRNA methods that quickly brought COVID-19 vaccines to the market as an answer to better flu vaccines.
- A Universal Flu Vaccine Is Getting Closer to Reality
This week, the U.S. National Institutes of Health announced the start of a phase I clinical trial testing out a potential universal flu vaccine. The safety and immune response of the experimental shot ...
- A Universal Flu Vaccine Is Getting Closer to Reality
This week, the U.S. National Institutes of Health announced the start of a phase I clinical trial testing out a potential universal flu vaccine. The safety and immune response of the experimental ...
Go deeper with Google Headlines on:
Experimental flu vaccine
[google_news title=”” keyword=”experimental flu vaccine” num_posts=”5″ blurb_length=”0″ show_thumb=”left”]
Go deeper with Bing News on:
Nanoparticle flu vaccine
- Influenza Vaccination in Immunocompromised Patients
Yearly administration of the influenza vaccine is the main strategy to prevent influenza in immunocompromised patients. Here, we reviewed the recent literature regarding the clinical significance ...
- Instant Inkjet Circuits With Silver Nanoparticle Ink
Researchers at the University of Tokyo, Georgia Tech and a team from Microsoft Research have developed a low-cost method of printing circuits using an ordinary inkjet printer using a technique ...
- Cold and Flu News
May 31, 2023 — Influenza epidemics, caused by influenza A or B viruses, result in acute respiratory infection. They kill half a million people worldwide every year. These viruses can also wreak ...
- Nanoparticles and the Blood Coagulation System
As such, nanoparticles are rapidly entering various areas of industry, biology and medicine. The benefits of using nanotechnology for industrial and biomedical applications are often tempered by ...
- I'm over 65 and worried about the flu. Which vaccine should I have?
Influenza, or the flu, is a virus transmitted by respiratory droplets from coughing and sneezing. It can cause the sudden onset of a fever, cough, runny nose, sore throat, headache, muscle and joint ...
Go deeper with Google Headlines on:
Nanoparticle flu vaccine
[google_news title=”” keyword=”nanoparticle flu vaccine” num_posts=”5″ blurb_length=”0″ show_thumb=”left”]